Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239077 | 0.90 | HCRTR2 (0.41) | ASAH1HCRTR2GPR119 | |
| SCHEMBL26238972 | 0.80 | ASAH1 (0.39) | ASAH1AOC3P2RX3HCRTR2GPR119 | |
| SCHEMBL26239074 | 0.79 | KCNH2 (0.44) | — | |
| SCHEMBL25388839 | 0.78 | MEN1 (0.35) | AOC3 | |
| SCHEMBL26238977 | 0.70 | ASAH1 (0.41) | ASAH1HCRTR2GPR119DRD2HTR2A | |
| SCHEMBL26239145 | 0.70 | ADRA1D (0.39) | DRD2HTR2A | |
| SCHEMBL26239068 | 0.69 | P2RX3 (0.40) | ASAH1P2RX3HCRTR2 | |
| SCHEMBL26238978 | 0.67 | USP30 (0.43) | ASAH1HCRTR2DRD2USP30 | |
| SCHEMBL25391308 | 0.66 | PRCP (0.47) | — | |
| SCHEMBL26238976 | 0.65 | ASAH1 (0.42) | ASAH1HCRTR2GPR119DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4472947-A1 | SWEETENER COMPOSITIONS | Firmenich Incorporated (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | GPR119, TAS2R50, TAS2R30 | ASAH1 239/4885AOC3 2739/4885P2RX3 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.